These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. Lappalainen J; Hietala J; Koulu M; Seppälä T; Sjöholm B; Syvälahti E J Pharmacol Exp Ther; 1990 Feb; 252(2):845-52. PubMed ID: 2179533 [TBL] [Abstract][Full Text] [Related]
4. Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Lappalainen J; Hietala J; Pohjalainen T; Syvälahti E Eur J Pharmacol; 1992 Jan; 210(2):195-200. PubMed ID: 1534766 [TBL] [Abstract][Full Text] [Related]
5. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Costall B; Naylor RJ Eur J Pharmacol; 1976 Nov; 40(1):9-19. PubMed ID: 791660 [TBL] [Abstract][Full Text] [Related]
6. Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices. Tedford CE; Crosby G; Iorio LC; Chipkin RE Eur J Pharmacol; 1992 Feb; 211(2):169-76. PubMed ID: 1535318 [TBL] [Abstract][Full Text] [Related]
7. Quantitative radioimmunocytochemical evidence that haloperidol and SCH 23390 induce opposite changes in substance P levels of rat substantia nigra. Cruz CJ; Beckstead RM Brain Res; 1988 Aug; 457(1):29-43. PubMed ID: 2458801 [TBL] [Abstract][Full Text] [Related]
8. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
9. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084 [TBL] [Abstract][Full Text] [Related]
11. D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons. Goldstein JM; Litwin LC; Sutton EB; Malick JB Life Sci; 1987 Mar; 40(11):1039-44. PubMed ID: 2950291 [TBL] [Abstract][Full Text] [Related]
12. The D1 dopamine receptor antagonist SCH 23390 enhances REM sleep in the rat. Trampus M; Ongini E Neuropharmacology; 1990 Oct; 29(10):889-93. PubMed ID: 2147740 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological and behavioral effects of D1 dopamine antagonists. Barnett A; Iorio LC; McQuade R; Chipkin RE Adv Exp Med Biol; 1988; 235():137-44. PubMed ID: 2976247 [TBL] [Abstract][Full Text] [Related]
14. [125I]SCH 23982: the ligand of choice for identifying the D-1 dopamine receptor. Sidhu A; van Oene JC; Dandridge P; Kaiser C; Kebabian JW Eur J Pharmacol; 1986 Sep; 128(3):213-20. PubMed ID: 2947806 [TBL] [Abstract][Full Text] [Related]
15. Binding characteristics of the dopamine agonist/antagonist [3H]terguride (transdihydrolisuride) in the rat striatum. Valchár M; Vrsecká M; Krejcí I; Dlabac A Eur J Pharmacol; 1987 Apr; 136(1):97-101. PubMed ID: 3297739 [TBL] [Abstract][Full Text] [Related]
16. Neurophysiological evidence that D-1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists. Carlson JH; Bergstrom DA; Walters JR Eur J Pharmacol; 1986 Apr; 123(2):237-51. PubMed ID: 2940101 [TBL] [Abstract][Full Text] [Related]
17. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Caine SB; Heinrichs SC; Coffin VL; Koob GF Brain Res; 1995 Sep; 692(1-2):47-56. PubMed ID: 8548319 [TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with SCH 23390, a selective dopamine D-1 receptor antagonist, decreases dopamine metabolism in rat caudate nucleus. Koulu M; Lappalainen J; Pesonen U; Hietala J; Syvälahti E Eur J Pharmacol; 1988 Oct; 155(3):313-6. PubMed ID: 3069483 [TBL] [Abstract][Full Text] [Related]
19. Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. Memo M; Pizzi M; Nisoli E; Missale C; Carruba MO; Spano P Eur J Pharmacol; 1987 Jun; 138(1):45-51. PubMed ID: 2887436 [TBL] [Abstract][Full Text] [Related]
20. Evidence for a fast receptor turnover of D1 dopamine receptors in various forebrain regions of the rat. Fuxe K; Agnati LF; Merlo Pich E; Meller E; Goldstein M Neurosci Lett; 1987 Oct; 81(1-2):183-7. PubMed ID: 3320818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]